Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BreathSpec

Financiado

Cerrado

A rapid non invasive cost effective analytical device for bacterial or viral...

A rapid non invasive cost effective analytical device for bacterial or viral infection diagnosis through ultra high sensitivity breath analysis. The world faces a growing epidemic of antimicrobial resistance (AMR); however, only two new classes of antibiotics have been brought to the market in the last 30 years. The discovery and development of new antibiotics is essential... ver más

31/07/2019

IMSPEX DIAGNOSTICS...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

IMSPEX DIAGNOSTICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-07-31

FTIPilot-01-2016: Fast Track to Innovation Pilot

I+D

Cerrada hace 8 años

0% 71% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

IMSPEX DIAGNOSTICS LIMITED

1.14M€ | Lider

CYPE SOFT

582.43K€ | Participante

REDKNIGHT CONSULTANCY LTD

116.29K€ | Participante

UNIVERSITY OF WARWICK

140.42K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

C4L Chips for Life 4M€ Cerrado

RAPP-ID Development of RApid Point of Care test Platforms for Infect... 16M€ Cerrado

TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND... 8M€ Cerrado

ResisCHIP Rapid chip-based detection of antibiotic resistances 150K€ Cerrado

RAPP-ID Development of RApid Point-of-Care test Platforms for Infect... 16M€ Cerrado

AntibioDx AntibioDx A groundbreaking in vitro diagnostic device with... 71K€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2017-05-11
Fecha Fin: 2019-07-31

Líder del proyecto

IMSPEX DIAGNOSTICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The world faces a growing epidemic of antimicrobial resistance (AMR); however, only two new classes of antibiotics have been brought to the market in the last 30 years. The discovery and development of new antibiotics is essential to maintain medical advances but poses significant scientific, clinical, and financial challenges, particularly for antibiotics active against Gram-negative bacteria (such as E. coli). Such bacteria have effective barriers against drugs, making treatment difficult, resistance likely and development costs and risks high. In addition, any new antibiotics brought to the market would likely be used cautiously to delay the development of resistance, adding an additional financial challenge in recouping the development costs. The O’Neill Report on AMR identifies diagnostics as critical to the battle against antibiotic resistance. This innovation action, BreathSpec, proposes a viable solution to the global problem of AMR through the final developmental stages of an existing diagnostic device, which will allow a rapid, binary decision to be made on the need for antibiotic treatment, and which with suitable optimisation will allow further differentiation and stratification to take place. The Innovation Action includes technical developments to optimise its function, data acquisition for the development of the decision making analytical function and clinical validation. It addresses these issues by producing reliable identification and quantification of key signature volatiles present in exhaled breath. It provides a non-invasive method for monitoring the volatile organic compounds present in an individual’s exhaled breath (and subsequently the blood) and has long been recognised as having significant utility as a clinical test that can be used for early disease detection and monitoring, and potentially to diagnose specific bacterial infections for better, more targeted use of existing antibiotics.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores